TIM-4

TIM-4 Molekülinformation

Englischer Name	T-cell immunoglobulin and mucin domain-containing protein 4	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1	Target-Alias	T-cell immunoglobulin mucin receptor 4 (TIM-4)，T-cell membrane protein 4，TIM4
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

Englischer Name	T-cell immunoglobulin and mucin domain-containing protein 4
Target-Alias	T-cell immunoglobulin mucin receptor 4 (TIM-4)，T-cell membrane protein 4，TIM4
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

TIM-4 Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (1)Cynomolgus (1)
Etikett
His Tag (2)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
TI4-H52H3	Human	HEK293	Human TIM-4 / TIMD4 Protein, His Tag				In den Warenkorb legen
TI4-C52H3	Cynomolgus	HEK293	Cynomolgus TIM-4 / TIMD4 Protein, His Tag (MALS verified)				In den Warenkorb legen

Gesamtmenge2

TIM-4 Molekülhintergrund

The T cell immunoglobulin mucin (TIM) proteins regulate T cell activation and tolerance. An essential step during clearance of apoptotic cells is the recognition of phosphatidylserine (PS) exposed on apoptotic cells by its receptors on phagocytes. The phosphatidylserine (PS) receptor Tim-4 mediates phagocytosis of apoptotic cells by binding to PS exposed on the surface of these cells, and thus functions as a PS receptor for apoptotic cells. Tim-4 directly binding to PS and functioning as a tethering receptor for phagocytosis of apoptotic cells has been extensively studied over the past decade. However, the molecular mechanisms by which Tim-4 collaborates with other engulfment receptors during efferocytosis remain elusive.

TIM-4 Molekülalias

TIM4,TIMD4,SMUCKLER

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
LPX-TI641	LPX-TI-641	Phase 1 Clinical	LAPIX Therapeutics Inc	Arthritis, Psoriatic; Arthritis, Rheumatoid; Autoimmune Diseases; Demyelinating Diseases; Dermatitis, Atopic; Multiple Sclerosis; Neuromyelitis Optica; Psoriasis	Details